Cargando…

AGITATION IN ALZHEIMER'S DISEASE: A DECISION TREE FOR HEALTHCARE PROVIDERS

Agitation in Alzheimer's Disease (AAD) impacts nearly 80% of persons with Alzheimer's Disease and is a cause of significant distress for patients and family/professional caregivers.Clinicians need guidance relative to assessment as well as non-pharmacologic and pharmacologic treatment appr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grossberg, George, Sanford, Angela, Scanland, Susan, Tracy, Karen, Stefanacci, Richard G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9771041/ http://dx.doi.org/10.1093/geroni/igac059.2013

Ejemplares similares

Brexpiprazole for the Treatment of Agitation in Alzheimer Dementia: A Randomized Clinical Trial
por: Lee, Daniel, et al.
Publicado: (2023)

Development of a Claims-Based Algorithm to Identify Patients With Agitation in Alzheimer’s Dementia
por: Hwang, Steve, et al.
Publicado: (2020)

Deuterated dextromethorphan/quinidine for agitation in Alzheimer's disease
por: Khoury, Rita
Publicado: (2021)

Agitation in Alzheimer's disease: Novel outcome measures reflecting the International Psychogeriatric Association (IPA) agitation criteria
por: De Mauleon, Adelaide, et al.
Publicado: (2021)

Institutionalization risk and costs associated with agitation in Alzheimer's disease
por: Cloutier, Martin, et al.
Publicado: (2019)

ELECTROCONVULSIVE THERAPY FOR AGITATION IN LEWY BODIES DEMENTIA
por: Echeverria, C., et al.
Publicado: (2023)

Perspectives of Persons With Dementia, Family, and Healthcare Providers on an Advance Care Planning Decision Aid
por: Geshell, Lisa, et al.
Publicado: (2020)

Application of the decision tree model in ADHD screening
por: Carreiro, L.R., et al.
Publicado: (2021)

A reflection on the use of Antidepressants to manage agitation in dementia
por: Basto, M.D.R.D.R.F.D., et al.
Publicado: (2022)

Optimal nonpharmacological management of agitation in Alzheimer’s disease: challenges and solutions
por: Millán-Calenti, José Carlos, et al.
Publicado: (2016)

2107. Decision Trees vs. Neural Networks for Supervised Machine Learning-Based Prediction of Healthcare-Associated Urinary Tract Infections
por: Zachariah, Philip, et al.
Publicado: (2018)

Impact of agitation in long‐term care residents with dementia in the United States
por: Fillit, Howard, et al.
Publicado: (2021)

1536. Acceptability of an HIV Pre-Exposure Prophylaxis (PrEP) Shared Decision-Making Tool for Diverse Populations and Healthcare Providers
por: Davis, Wendy W, et al.
Publicado: (2023)

Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease
por: Babapour Mofrad, Rosha, et al.
Publicado: (2018)

1822. Veterans Are Special: Clinical Decision Tree Misses ESBL Status in Bacteremic Veterans
por: Chou, Andrew, et al.
Publicado: (2018)

Neural basis of three dimensions of agitated behaviors in patients with Alzheimer disease
por: Banno, Koichi, et al.
Publicado: (2014)

Severe agitation in severe early-onset Alzheimer’s disease resolves with ECT
por: Aksay, Suna Su, et al.
Publicado: (2014)

Plasma biomarkers are associated with agitation and regional brain atrophy in Alzheimer’s disease
por: Hsu, Jung-Lung, et al.
Publicado: (2017)

An Agitated Patient With COVID-19 Infection and Early-onset Alzheimer Disease
por: Sykora, Daniel, et al.
Publicado: (2022)

Passive Infrared Motion Sensors Improved the Detection Accuracy of Nocturnal Agitation
por: Au-Yeung, Wan-Tai, et al.
Publicado: (2021)

Decision tree analysis of genetic risk for clinically heterogeneous Alzheimer’s disease
por: Yokoyama, Jennifer S, et al.
Publicado: (2015)

Circadian Rhythm Disturbances in Patients with Alzheimer's Disease: A Review
por: Weldemichael, Dawit A., et al.
Publicado: (2010)

POTENTIAL BENEFITS OF THC AND CBD IN THE TREATMENT OF HOSPICE-ELIGIBLE DEMENTED AND AGITATED PATIENTS
por: Mintzer, Jacobo`
Publicado: (2022)

Decision tree–based classifier in providing telehealth service
por: Chern, Ching-Chin, et al.
Publicado: (2019)

Using electronic health records to estimate the prevalence of agitation in Alzheimer disease/dementia
por: Halpern, Rachel, et al.
Publicado: (2018)

Enhancing Provider Reporting of Notifiable Diseases using HIE-enabled Decision Support
por: Dixon, Brian E., et al.
Publicado: (2019)

Using a Virtual Curriculum to Provide Interprofessional Student Education in Alzheimer’s Disease
por: Indelicato, Alyssa, et al.
Publicado: (2020)

Choosing Unwisely: Dissemination Needs of Primary Care Providers of Patients with Alzheimer’s Disease
por: Lindquist, Lee, et al.
Publicado: (2021)

Factor Analysis of the Short Form Cohen Mansfield Agitation Inventory and Measurement Invariance by Gender
por: Paudel, Anju, et al.
Publicado: (2020)

Episodes of aggression and psychomotor agitation in psychiatric inpatients during the period of Covid-19 pandemia
por: Franza, F., et al.
Publicado: (2023)

The effect of wearable technology on psychomotor agitation in patients with diagnostic patients with schizophrenia expansion and psychosis
por: Oflaz, F., et al.
Publicado: (2023)

On Agitation
Publicado: (1920)

Multidisciplinary Healthcare Providers’ Perspectives on Managing Suspected Elder Abuse in the Healthcare Setting
por: Makaroun, Lena, et al.
Publicado: (2020)

Effects of Animal-Assisted Therapy on Verbal Communication and Agitation in Adults With Dementia in Long-Term Care
por: Woltman, Jenilee, et al.
Publicado: (2020)

REMOTE ELECTRONIC DATA CAPTURE OF MEDICATION USE AND AGITATION SYMPTOMS IN OLDER ADULTS WITH MCI OR DEMENTIA
por: Au-Yeung, Wan-Tai, et al.
Publicado: (2022)

Changes in QTc Interval in the Citalopram for Agitation in Alzheimer's Disease (CitAD) Randomized Trial
por: Drye, Lea T., et al.
Publicado: (2014)

A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer’s disease patients with agitation
por: Akil, Ayman, et al.
Publicado: (2015)

Monetary costs of agitation in older adults with Alzheimer's disease in the UK: prospective cohort study
por: Morris, Stephen, et al.
Publicado: (2015)

New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer’s disease: focus on brexpiprazole and pimavanserin
por: Caraci, Filippo, et al.
Publicado: (2020)

Heart rate variability and risk of agitation in Alzheimer’s disease: the Atherosclerosis Risk in Communities Study
por: Liu, Kathy Y, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bdqjlnp1q6rr7gvra8le93aq17